Ionizing radiation-induced foci persistence screen to discover enhancers of accelerated senescence

References

• Van Attikum H, Gasser SM. Crosstalk between histone modifications during the DNA damage response. Trends Cell Biol. 2009;19(5):207–217.
   PubMed Web of Science ®Google Scholar
• Corpet A, Almouzni G. A histone code for the DNA damage response in mammalian cells? The EMBO Journal. 2009;28(13):1828.
   Web of Science ®Google Scholar
• Rossetto D, Truman AW, Kron SJ, Cote J. Epigenetic modifications in double-strand break DNA damage signaling and repair. Clin Cancer Res. 2010;16(18):4543–4552.
   PubMed Web of Science ®Google Scholar
• Hollick JJ, Rigoreau LJ, Cano-Soumillac C, et al. Pyranone, thiopyra- none, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. J Med Chem. 2007;50(8):1958–1972.
   Web of Science ®Google Scholar
• Peterson S, Wang L, Robertson K, et al. Reply to “Corrected structure of mirin, a small-molecule inhibitor of the Mre11-Rad50-Nbs1 complex”. Nat Chem Biol. 2009;5(3):130.
   Web of Science ®Google Scholar
• Garner K, Pletnev A, Eastman A. Corrected structure of mirin, a small- molecule inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2009;5(3):129–130.
   PubMed Web of Science ®Google Scholar
• Dupre A, Boyer-Chatenet L, Sattler R, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2008;4:119–125.
   PubMed Web of Science ®Google Scholar
• Won J, Kim M, Kim N, et al. Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006;2(7):369–374.
   PubMed Web of Science ®Google Scholar
• Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008;8(12):957–967.
   PubMed Web of Science ®Google Scholar
• Belyaev IY. Radiation-induced DNA repair foci: spatio-temporal aspects of formation, application for assessment of radiosensitivity and biological dosimetry. Mutat Res. 2010;704(1–3):132–141.
   PubMed Web of Science ®Google Scholar
• Yamauchi M, Oka Y, Yamamoto M, et al. Growth of persistent foci of DNA damage checkpoint factors is essential for amplification of G1 checkpoint signaling. DNA Repair (Amst). 2008;7(3):405–417.
   PubMed Web of Science ®Google Scholar
• Liu SK, Olive PL, Bristow RG. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev. 2008;27(3):445–458.
   PubMed Web of Science ®Google Scholar
• Banath JP, Klokov D, MacPhail SH, et al. Residual gammaH2AX foci as an indication of lethal DNA lesions. BMC Cancer. 2010;10:4.
   PubMed Web of Science ®Google Scholar
• Camphausen K, Burgan W, Cerra M, et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004;64(1):316–321.
   PubMed Web of Science ®Google Scholar
• Taneja N, Davis M, Choy JS, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004;279(3):2273–2280.
   Web of Science ®Google Scholar
• Rodier F, Coppe JP, Patil CK, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973–979.
   PubMed Web of Science ®Google Scholar
• Nakamura AJ, Chiang YJ, Hathcock KS, et al. Both telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescence. Epigenetics Chromatin. 2008;1(1):6.
   PubMed Web of Science ®Google Scholar
• D’Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512–522.
   PubMed Web of Science ®Google Scholar
• Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 2001;4(5):303–313.
   PubMed Web of Science ®Google Scholar
• Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010;102(20):1536–1546.
   Google Scholar
• Schmitt C. Cellular senescence and cancer treatment. BBA-Reviews on Cancer. 2007;1775(1):5–20.
   PubMed Web of Science ®Google Scholar
• Bilsland AE, Keith WN. Mining cellular senescence for drug targets. Cellular Senescence and Tumor Suppression. Adams PD, Sedivy JM, editors. Philadelophia: Springer Science+Business Media, LLC; 2010:235–265.
   Google Scholar
• Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003;63(11):2705–2715.
   PubMed Web of Science ®Google Scholar
• Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656–660.
   PubMed Web of Science ®Google Scholar
• Krizhanovsky V Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657–667.
   PubMed Web of Science ®Google Scholar
• Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010;24(22):2463–2479.
   PubMed Web of Science ®Google Scholar
• Gewirtz DA, Holt SE, Elmore LW. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol. 2008;76(8):947–957.
   PubMed Web of Science ®Google Scholar
• Kim K, Pollard J, Norris A, et al. High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res. 2009;15(23):7238.
   PubMed Web of Science ®Google Scholar
• Lawless C, Wang C, Jurk D, et al. Quantitative assessment of markers for cell senescence. Exp Gerontol. 2010;45(10):772–778.
   PubMed Web of Science ®Google Scholar
• Huyen Y, Zgheib O, Ditullio RA Jr, et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature. 2004;432(7015):406–411.
   PubMed Web of Science ®Google Scholar
• Efimova EV Mauceri HJ, Golden DW, et al. Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res. 2010;70(15):6277–6282.
   PubMed Web of Science ®Google Scholar
• Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4(2):67–73.
   PubMed Web of Science ®Google Scholar
• Yoo E, Kim BU, Lee SY, et al. 53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damage. Oncogene. 2005;24(35):5423–5430.
   Web of Science ®Google Scholar
• Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 2008;9(4):297–308.
   PubMed Web of Science ®Google Scholar
• Chen TC, Wadsten P, Su S, et al. The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol Ther. 2002;1(3):268–276.
   PubMed Web of Science ®Google Scholar
• Goldhoff P, Warrington NM, Limbrick DD Jr, et al. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res. 2008;14(23):7717–7725.
   PubMed Web of Science ®Google Scholar
• Penning TD, Zhu GD, Gandhi VB, et al. Discovery of the poly(ADP- ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin- 2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009;52(2):514–523.
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Penning TD, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA- damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13(9):2728–2737.
   PubMed Web of Science ®Google Scholar
• Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007;8(9):729–740.
   PubMed Web of Science ®Google Scholar
• Falk M, Lukasova E, Kozubek S. Higher-order chromatin structure in DSB induction, repair and misrepair. Mutat Res. 2010;704(1–3):88–100.
   PubMed Web of Science ®Google Scholar
• Katz D, Ito E, Liu FF. On the path to seeking novel radiosensitizers. Int JRadiat Oncol Biol Phys. 2009;73(4):988–996.
   Web of Science ®Google Scholar
• Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol). 2007;19(6):397–417.
   Web of Science ®Google Scholar
• Michod D, Widmann C. DNA-damage sensitizers: potential new therapeutical tools to improve chemotherapy. Critical Reviews in Oncology and Hematology. 2007;63(2):160–171.
   Web of Science ®Google Scholar
• Bolderson E, Richard D, Zhou B, Khanna K. Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res. 2009;15(20):6314.
   PubMed Web of Science ®Google Scholar
• Tofilon PJ, Camphausen K. Molecular targets for tumor radiosensitization. Chem Rev. 2009;109(7):2974–2988.
   Web of Science ®Google Scholar
• Zhu Y, Hu J, Hu Y, Liu W. Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance. Cancer Treat Rev. 2009;35(7):590–596.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm: general principles. Nat Clin Pract Oncol. 2007;4(2):86–100.
   PubMedGoogle Scholar
• Jackson S, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–1078.
   PubMed Web of Science ®Google Scholar
• Damia G, D’lncalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer. 2007;43(12):1791–1801.
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193–204.
   PubMed Web of Science ®Google Scholar
• O’Connor MJ, Martin NM, Smith GC. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene. 2007;26(56):7816–7824.
   PubMed Web of Science ®Google Scholar
• Zhou BB, Sausville EA. Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res. 2003;5:413–421.
   PubMedGoogle Scholar
• Luo Y, Leverson JD. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response. Expert Rev Anticancer Ther. 2005;5(2):333–342.
   PubMed Web of Science ®Google Scholar
• Ewald JA, Peters N, Desotelle JA, et al. A high-throughput method to identify novel senescence-inducing compounds. J Biomol Screen. 2009;14(7):853–858.
   Google Scholar
• Chong C, Sullivan D Jr. New uses for old drugs. Nature. 2007;448(7154):645.
   PubMed Web of Science ®Google Scholar
• Ashburn T, Thor K. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683.
   PubMed Web of Science ®Google Scholar
• Lipinski C, Lombardo F, Dominy B, Feeney P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25.
   Web of Science ®Google Scholar
• Wermuth C. Selective optimization of side activities: the SOSA approach. Drug Discov Today. 2006;11(3^):160–164.
   Web of Science ®Google Scholar